Related Experiment Videos
Cerebral thrombosis and oral contraceptives. A case-control study
1Department of Obstetrics and Gynecology, Herlev Hospital, University of Copenhagen, Denmark.
Contraception
|July 23, 1998
Summary
Oral contraceptives (OC) containing 50 micrograms of ethinyl estradiol (EE) and second-generation progestins significantly increase the risk of cerebral thromboembolic attacks (CTA). Third-generation OC and former OC use did not show a significant risk increase for CTA.
Area of Science:
- Neurology
- Pharmacology
- Epidemiology
Background:
- Cerebral thrombosis and transient cerebral ischemic attacks are serious neurological events.
- Oral contraceptives (OC) are widely used by women of reproductive age.
- Understanding the association between OC use and cerebrovascular events is crucial for patient safety.
Purpose of the Study:
- To evaluate the association between oral contraceptive use and the risk of cerebral thromboembolic attacks (CTA).
- To investigate the influence of different generations and ethinyl estradiol (EE) dosages of OC on CTA risk.
Main Methods:
- A 5-year case-control study was conducted across Danish hospitals.
- Included were women aged 15-44 who experienced a CTA and age-matched controls.
- Data were collected via questionnaires, with statistical analysis performed after confounder control.
Main Results:
- Current users of OC with 50 micrograms EE had an odds ratio (OR) of 2.65 for CTA.
- Second-generation OC (levonorgestrel, norgestimate) users showed a significantly increased OR of 2.37.
- Third-generation OC users and former OC users did not exhibit a significantly increased risk of CTA.
Conclusions:
- Oral contraceptives containing 50 micrograms EE and second-generation progestins are associated with a significantly increased risk of cerebral thromboembolic attacks.
- Third-generation OC do not appear to significantly elevate CTA risk.
- The risk of CTA is not elevated among former oral contraceptive users.